Previous studies have revealed that HDAC6 inhibitors might suppress the growth of a panel of human melanoma cell lines and could be a potential strategy for melanoma therapy, even resolving vemurafenib resistance (53, 54). The gene discussed is HDAC6; the disease is melanoma.